NEW YORK (GenomeWeb News) – The non-profit Battelle Eastern Science and Technology Center will conduct performance verification studies of IntelligentMDx’s molecular diagnostic assays, the company said today.
Battelle, which is headquartered in Columbus, Ohio, will perform various tests of the company’s Quantitative BK Virus Real-Time PCR Assay to identify its performance characteristics.
BKV is an important pathogen involved in nephrophathy in kidney transplant patients and hemorrhagic cystitis in stem cell transplant patients. The IntelligentMDx test has been developed to track the course of infection and to monitor the response to treatment.
Financial terms of the agreement were not released.